Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease
News
Redefining trial access
Re:Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials
Strong clinical data for Breye lead asset danegaptide
Oral candidate shows favourable safety profile and signs of clinical activity in NPDR
EHP Awards triumph
Recognising the achievements of this year’s standout healthcare collaborations
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
The US sees around 476,000 new Lyme cases every year
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys
CERo reports encouraging early data from phase 1 trial of CER‑1236
CER‑T therapy shows initial safety signals and prompts protocol expansion
ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
Trial to assess whether once‑weekly treatment can reduce symptomatic viral respiratory infections
Argo Biopharma doses first patient in phase 2b trial of BW‑20829
siRNA therapeutic progresses in global study for patients with elevated Lp(a)
Akari files new patent and advances second ADC targeting CEACAM5
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate
BioMed X launches kidney disease project in partnership with the government of Barbados
Initiative focuses on population-specific molecular profiling
Gedeon Richter UK takes over UK rights to cariprazine
Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati
Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo
